Purpose: To describe 2 cases of vitreoretinal metastases in patients treated with immunotherapy for metastatic melanoma. Methods: Retrospective case series. Results: We pre-sent 2 patients with metastatic melanoma treated with systemic immunotherapy with subsequent development of ocular vitreoretinal metastasis. The first patient was a male with metastatic melanoma from a site of unknown origin that was in complete remission following a course of ipilimumab and nivolumab therapy. He presented to an outside provider for evaluation of vitritis and a pigmented lesion in the right eye that was presumed secondary to toxoplasmosis. After failing initial management with oral antibiotics, he underwent diagnostic pars plana vitrectomy, and vitreous biopsy was consistent with metastatic melanoma to the vitreous. He was additionally found to have an elevated pigmented retinal mass consistent with a retinal metastasis from melanoma that initially failed treatment with plaque brachytherapy and ultimately required enucleation. The second case was a monocular male with metastatic melanoma from cutaneous melanoma with decreased vision 3 months after the initiation of nivolumab therapy. He presented with dense vitreous debris in his seeing eye and was thought to have nivolumab-associated inflammation. He was initially treated with difluprednate with improved vision and decrease in vitreous debris, but developed dense pigment deposition in the affected eye later in the treatment course. Diagnostic pars plana vitrectomy was performed, and vitreous biopsy was positive for malignant melanoma cells. His systemic disease was in remission at the time of diagnosis of ocular metastasis. External beam radiation was recommended given his monocular status. Conclusion: Vitreoretinal metastasis can develop despite favorable systemic response to immunotherapy in patients with metastatic cutaneous melanoma. Lack of ocular penetration and extension of life span with immunotherapeutic agents may be the underlying mechanism for vitreoretinal metastasis.

1.
Shields
CL
,
Shields
JA
,
Gross
NE
,
Schwartz
GP
,
Lally
SE
.
Survey of 520 eyes with uveal metastases
.
Ophthalmology
.
1997
Aug
;
104
(
8
):
1265
76
.
[PubMed]
0161-6420
2.
Shields
CL
,
McMahon
JF
,
Atalay
HT
,
Hasanreisoglu
M
,
Shields
JA
.
Retinal metastasis from systemic cancer in 8 cases
.
JAMA Ophthalmol
.
2014
Nov
;
132
(
11
):
1303
8
.
[PubMed]
2168-6165
3.
Apte
RS
,
Dibernardo
C
,
Pearlman
JR
,
Patel
S
,
Schachat
AP
,
Green
WR
, et al.
Retinal metastasis presenting as a retinal hemorrhage in a patient with adenocarcinoma of the cecum
.
Arch Ophthalmol
.
2005
Jun
;
123
(
6
):
850
3
.
[PubMed]
0003-9950
4.
Letson
AD
,
Davidorf
FH
.
Bilateral retinal metastases from cutaneous malignant melanoma
.
Arch Ophthalmol
.
1982
Apr
;
100
(
4
):
605
7
.
[PubMed]
0003-9950
5.
Kim
CY
,
Ha
CW
,
Lee
SC
.
Vitreous and retinal metastasis from gastric cancer
.
Eur J Ophthalmol
.
2010
May-Jun
;
20
(
3
):
615
7
.
[PubMed]
1120-6721
6.
Mack
HG
,
Jakobiec
FA
.
Isolated metastases to the retina or optic nerve
.
Int Ophthalmol Clin
.
1997
;
37
(
4
):
251
60
.
[PubMed]
0020-8167
7.
H.
Krema
,
B.
Fernandes
,
R.
Simpson
,
C.
Lutchman
, and
Y.
Yucel
, “
Diffuse metastatic melanoma to the retina: a clinicopathologic report
,” Can. J. Ophthalmol. Can. d’ophtalmologie, vol. 48, no. 2, pp. e20–e21,
2013
.
8.
Rosenberg
C
,
Finger
PT
.
Cutaneous malignant melanoma metastatic to the eye, lids, and orbit
.
Surv Ophthalmol
.
2008
May-Jun
;
53
(
3
):
187
202
.
[PubMed]
0039-6257
9.
Breazzano
MP
,
Barker-Griffith
AE
.
Features of Cutaneous Malignant Melanoma Metastatic to the Retina and Vitreous
.
Ocul Oncol Pathol
.
2015
Dec
;
2
(
2
):
80
5
.
[PubMed]
2296-4681
10.
Kanavati
S
,
Ottensmeier
C
,
Foria
V
,
Krishnan
R
.
Bilateral Metastatic Cutaneous Melanoma To Retina and Vitreous After Ipilimumab Treated With Pars Plana Vitrectomy and Radiotherapy
.
Retin Cases Brief Rep
.
2018
;
12
(
3
):
184
7
.
[PubMed]
1935-1089
11.
Manusow
JS
,
Khoja
L
,
Pesin
N
,
Joshua
AM
,
Mandelcorn
ED
.
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
.
2014
. pp.
1
4
.
12.
Sia
DI
,
Thaung
C
,
O’Hanlon-Brown
C
,
Cohen
VM
,
Sagoo
MS
.
Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye
.
Melanoma Res
.
2018
Aug
;
28
(
4
):
359
62
.
[PubMed]
0960-8931
13.
Franklin
C
,
Livingstone
E
,
Roesch
A
,
Schilling
B
,
Schadendorf
D
.
Immunotherapy in melanoma: recent advances and future directions
.
Eur J Surg Oncol
.
2017
Mar
;
43
(
3
):
604
11
.
[PubMed]
0748-7983
14.
Dalvin
LA
,
Shields
CL
,
Orloff
M
,
Sato
T
,
Shields
JA
.
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
.
Retina
.
2018
Jun
;
38
(
6
):
1063
78
.
[PubMed]
0275-004X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.